Special medical use infant formula for enhancing and / or improving social behavior of individual

Abstract

The present invention provides special medical use infant formulas useful for enhancing and / or improving the social behavior of an individual. The infant formula food for the special medical purpose comprises DHA, ARA and phospholipid, the phospholipid is sphingomyelin and / or lecithin, the mass ratio of the DHA to the phospholipid is (0.5-13): 1, and the mass ratio of the ARA to the phospholipid is (0.5-17): 1. The special medical use infant formula of the present invention contributes to enhancing and / or improving the social behavior of an individual.

Description

Technical Field

[0001] The present invention belongs to the technical field of special medical purpose formula foods, and specifically relates to a special medical purpose infant formula food containing DHA, ARA and phospholipids, which helps to enhance and / or improve individual social behavior and its application. Background Art

[0002] DHA (docosahexaenoic acid), ARA (arachidonic acid) and neuraminic acid are three important polyunsaturated fatty acids. DHA is a fatty acid that is mainly found in the brain, nerve tissue and retina. It not only constitutes an important component of these tissues, but also helps maintain the fluidity and stability of cell membranes. ARA is also an important fatty acid in the brain and is involved in the structure and function of nerve cells. As a special fatty acid, neuraminic acid is an important component of brain white matter and is indispensable for the health and development of the nervous system. In the current existing technology, DHA, ARA and neuraminic acid are usually added alone or in combination to infant or children's formula or nutritional products to enhance their nutritional functional value. However, most of the current studies on the effects of DHA, ARA and neuraminic acid on brain function focus on the effects of a single ingredient, while there are relatively few studies on the combined effects of these ingredients. In addition, there is still a lack of in-depth research on how to optimize the proportion and method of adding these ingredients to achieve the best nutritional effect.

[0003] Social behavior refers to an individual's ability to interact with people around him or her and to take care of himself or herself. It is one of the attributes for assessing the developmental behavior level of children aged 0 to 6 years old (under 7 years old).

[0004] Food for Special Medical Purpose (FSMP) is a specially processed and prepared food to meet the special needs of people with restricted food intake, digestive and absorption disorders, metabolic disorders or specific disease states for nutrients or diets. FSMP includes special medical formula for infants aged 0 to 12 months and special medical formula for people over 1 year old.

[0005] After searching, there are few reports in the prior art on whether diet affects individual social behavior and what kind of impact it has on individual social behavior. Summary of the invention

[0006] One object of the present invention is to provide a special medical purpose infant formula food which helps to greatly enhance and / or improve the social behavior of an individual.

[0007] Another object of the present invention is to provide related applications of the infant formula food for special medical purposes.

[0008] The present invention has found that polyunsaturated fatty acids (PUFAs) such as docosahexaenoic acid (DHA) and arachidonic acid (ARA), and a composition further comprising sphingomyelin (SM) and / or lecithin (i.e., a composition comprising DHA, ARA, sphingomyelin and / or lecithin), can affect the social behavior of an individual. In particular, when DHA, ARA and sphingomyelin, especially milk phospholipids (milk SM), are combined in a certain proportion, they have a synergistic effect on enhancing and / or improving the social behavior of an individual.

[0009] On the one hand, the present invention provides a special medical purpose infant formula food, which contains DHA, ARA, and phospholipids, and the phospholipids are sphingomyelin and / or lecithin, wherein the mass ratio of DHA to phospholipids (i.e., sphingomyelin and / or lecithin) is 0.5-13:1, and the mass ratio of ARA to phospholipids is 0.5-17:1.

[0010] According to a specific embodiment of the present invention, the infant formula for special medical purposes of the present invention is selected from one or more of the following: infant formula, lactose-free formula or low-lactose formula for infants, partially hydrolyzed milk protein formula for infants, deeply hydrolyzed milk protein formula for infants, and formula for premature / low birth weight infants.

[0011] According to a specific embodiment of the present invention, in the infant formula food for special medical purposes of the present invention, the mass ratio of DHA to ARA is 0.2-5:1.

[0012] According to a specific embodiment of the present invention, in the infant formula food for special medical purposes of the present invention, the mass ratio of DHA to ARA is 0.3-3:1.

[0013] According to some specific embodiments of the present invention, in the infant formula food for special medical purposes of the present invention, the mass ratio of DHA to ARA is preferably 0.5-2.5:1.

[0014] According to some specific embodiments of the present invention, in the infant formula food for special medical purposes of the present invention, the mass ratio of DHA to ARA is preferably 0.5-2:1.

[0015] According to some specific embodiments of the present invention, in the infant formula for special medical purposes of the present invention, the mass ratio of DHA to ARA is preferably 0.5-1.5:1, for example 0.5:1, 0.6:1, 0.67:1, 0.8:1, 1:1, 1.1:1, 1.2:1, 1.3:1 or 1.4:1.

[0016] According to some specific embodiments of the present invention, in the infant formula for special medical purposes of the present invention, the mass ratio of DHA to phospholipids is 0.5-8:1, for example, 0.5:1, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1 or 8:1.

[0017] According to some specific embodiments of the present invention, in the infant formula for special medical purposes of the present invention, the mass ratio of ARA to phospholipids is 0.5-10:1, for example 0.5:1, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1 or 10:1.

[0018] According to a specific embodiment of the present invention, in the infant formula food for special medical purposes of the present invention, when the phospholipids are sphingomyelin and lecithin, the amount of the phospholipids is the total amount of sphingomyelin and lecithin. Sphingomyelin and lecithin can be combined in any proportion.

[0019] According to some specific embodiments of the present invention, in the infant formula food for special medical purposes of the present invention, the phospholipid is sphingomyelin.

[0020] According to some specific embodiments of the present invention, in the infant formula food for special medical purposes of the present invention, the sphingomyelin is milk phospholipids.

[0021] According to some specific embodiments of the present invention, the infant formula for special medical purposes comprises DHA, ARA and milk lecithin.

[0022] According to a specific embodiment of the present invention, in the infant formula for special medical purposes of the present invention, the raw material for providing the DHA can be a commercially available DHA raw material with higher purity, or it can be a DHA oil and / or powder derived from one or a combination of two or more of algae, tuna oil, fish oil, milk-derived DHA from feed nutrition regulation and biotransformation, egg yolk extract and krill oil; wherein the algae can be one or a combination of two or more of Schizochytrium, Okenichytrium and Crypthecodinium. Unless otherwise specified, the ratio of the DHA to other functional components in the infant formula for special medical purposes of the present invention is based on the content of DHA in the raw material.

[0023] According to a specific embodiment of the present invention, in the infant formula for special medical purposes of the present invention, the raw material for providing the ARA can be a commercially available ARA raw material with higher purity, or can be one or more raw materials derived from algae and other oils containing ARA. Unless otherwise specified, the ratio of the ARA to other functional components in the infant formula for special medical purposes of the present invention is based on the content of ARA in the raw material.

[0024] According to a specific embodiment of the present invention, in the special medical purpose infant formula food of the present invention, the raw material for providing the sphingomyelin can be a commercially available sphingomyelin raw material with higher purity. Unless otherwise specified, the ratio of the sphingomyelin to other functional components in the special medical purpose infant formula food of the present invention is based on the content of sphingomyelin in the raw material. When the sphingomyelin in the special medical purpose infant formula food of the present invention is milk phospholipids, its ratio to other functional components is based on the content of milk phospholipids in the raw material.

[0025] According to a specific embodiment of the present invention, in the infant formula food for special medical purposes of the present invention, the amount of sphingomyelin contained in the food is 20-138 mg / 100 g of food dry matter, calculated based on the amount of sphingomyelin in the composition.

[0026] According to a specific embodiment of the present invention, the content of DHA and ARA in the infant formula for special medical purposes of the present invention can be determined according to the ratio with sphingomyelin.

[0027] According to a specific embodiment of the present invention, the infant formula for special medical purposes of the present invention preferably contains a total amount of DHA and ARA of 100-180 mg / 100 g of food dry matter.

[0028] It is understandable that for different types of special medical purpose infant formula, the content of each functional substance in the final product should be appropriately adjusted within the range permitted by relevant standards and specifications.

[0029] According to a specific embodiment of the present invention, the infant formula for special medical purposes of the present invention may further include other components of conventional infant formula for special medical purposes, such as protein, fat, carbohydrate, etc.

[0030] According to a specific embodiment of the present invention, in the infant formula for special medical purposes of the present invention, the protein may be a vegetable protein and / or an animal protein. In some specific embodiments of the present invention, the protein comprises milk protein, preferably selected from cow milk protein and / or goat milk protein. In some specific embodiments of the present invention, the protein may be, for example, a protein derived from cow milk, including cow milk whole protein, specifically commercially available milk protein powder or whey protein powder. In some specific embodiments of the present invention, the whey protein content in the protein is not less than 40%, preferably not less than 60%. For infant formula for special medical purposes, the protein therein is preferably partially hydrolyzed or deeply hydrolyzed. For infant formula for special medical purposes, the total protein therein is preferably 0.45g-0.7g / 100kJ.

[0031] According to a specific embodiment of the present invention, in the infant formula for special medical purposes of the present invention, the raw material for providing fat includes vegetable oil in addition to the basic raw material containing milk fat, and the vegetable oil may include but is not limited to one or more of sunflower oil, corn oil, soybean oil, rapeseed oil, coconut oil, palm oil, and walnut oil, preferably including sunflower oil, corn oil and soybean oil, and the addition of these vegetable oils provides fat components for the product on the one hand, and linoleic acid and α-linolenic acid on the other hand. In addition, the raw material for providing fat may also selectively include medium-chain triglycerides, and raw material OPO structural fat added to provide 1,3-dioleic acid-2-palmitoyl triglyceride. More preferably, based on 1000 parts by weight of infant formula for special medical purposes, its raw materials include but are not limited to: 0-150 parts by weight of sunflower oil; 0-50 parts by weight of corn oil; 0-80 parts by weight of soybean oil; 0-100 parts by weight of rapeseed oil; 0-150 parts by weight of medium-chain triglycerides; 0-140 parts by weight of OPO structural fat. For infant formula for special medical purposes, the total fat content is preferably 1.05g-1.40g / 100kJ.

[0032] According to a specific embodiment of the present invention, in the infant formula for special medical purposes of the present invention, carbohydrates come from lactose or non-lactose sources, including but not limited to pregelatinized starch, maltodextrin, solid corn syrup, glucose syrup, and partly from modified starch emulsifiers. Preferably, based on 1000 parts by weight of the infant formula for special medical purposes, its raw materials include but are not limited to: 0-580 parts by weight of lactose, 0-580 parts by weight of non-lactose substances. The specific addition amount can be adjusted within the range so that the carbohydrate content of the present invention is 50-58g / 100g. For infant formula for special medical purposes, the amount of carbohydrates therein should be 2.2g-3.3g / 100kJ.

[0033] According to a specific embodiment of the present invention, the raw materials of the infant formula for special medical purposes of the present invention further include, but are not limited to, one or more of appropriate EPA, nucleotides, lactoferrin, etc., and also include compound nutrients including calcium powder, vitamins and minerals. Preferably, based on 1000 parts by weight of the infant formula for special medical purposes, its raw materials include: EPA is 10-140 parts by weight; compound nutrients including calcium powder, vitamins and minerals are 7-60 parts by weight.

[0034] According to some preferred specific embodiments of the present invention, the infant formula for special medical purposes of the present invention is a formula for premature / low birth weight infants for special medical purposes. Based on 1000 parts by weight of the formula, the raw materials include: 0-200 parts by weight of hydrolyzed whey protein powder, 0-50 parts by weight of whey protein powder, 100-500 parts by weight of desalted whey powder, 0-100 parts by weight of casein; 0-10 parts by weight of phospholipids, 0-50 parts by weight of anhydrous butter, 0-50 parts by weight of solid corn syrup; ~400 weight parts, 0~400 weight parts of maltodextrin, 0~150 weight parts of sunflower oil, 0~40 weight parts of corn oil, 20~80 weight parts of soybean oil, 0~100 weight parts of medium chain triglycerides, 0~10 weight parts of tryptophan, 0~10 weight parts of arginine, 1~5 weight parts of complex vitamins, 0~3 weight parts of magnesium chloride, 0~3 weight parts of choline chloride, 0~2 weight parts of mineral one, 1~12 weight parts of mineral two, 0~15 weight parts of mineral three, 0~15 weight parts of DHA, 0~20 weight parts of ARA, 0~1.5 weight parts of nucleotides, and 0~2 weight parts of lactoferrin. Among them, mineral one, per gram of mineral one: iron 20~110mg; zinc 23~90mg; copper 2000~4180μg; iodine 500~995μg; selenium 0~200μg; manganese 0~579μg. Mineral 2, per gram of mineral 2: 40-100 mg sodium; 200-500 mg potassium. Mineral 3, per gram of mineral 3: 200-500 mg calcium; 75-300 mg phosphorus. Optionally, one or more of the following ingredients may be included: 0.20-2.04 parts by weight of inositol, 0-0.65 parts by weight of taurine, 0.06-0.5 parts by weight of L-carnitine, 3-18 parts by weight of DHA, 3-18 parts by weight of ARA, and 0-20 parts by weight of phospholipids.

[0035] The compound vitamins and various minerals in the formula of the special medical purpose premature / low birth weight infants of the present invention can be a composite nutrient composition of nutrients that meet national standards, and different addition amounts are used according to different formulas. The specific addition method can refer to the conventional operations in the relevant field. Preferably, if the product of the present invention adds composite nutrients as needed, any one or any combination of the following composite nutrient components can be selectively used:

[0036] Vitamin A: 1300~4000μgRE

[0037] Vitamin D: 24-60 μg

[0038] Vitamin E: 13-41 mg α-TE

[0039] Vitamin K1: 200-550 μg

[0040] Vitamin B1: 1500-6500 μg

[0041] Vitamin B2: 600-3000 μg

[0042] Vitamin B6: 1000-4000 μg

[0043] Vitamin B 12 :2~12μg

[0044] Nicotinamide: 12000~30000μg

[0045] Folic acid: 300-653 μg

[0046] Pantothenic acid: 8750-16230 μg

[0047] Biotin: 56-150 μg

[0048] Sodium: 30-350 mg

[0049] Potassium: 63-400 mg

[0050] Copper: 2200~5540μg

[0051] Magnesium: 50-400 mg

[0052] Iron: 23-95 mg

[0053] Zinc: 25-52 mg

[0054] Calcium: 110-300 mg

[0055] Phosphorus: 75-200 mg

[0056] Iodine: 200~1592μg.

[0057] It is understandable that for different types of special medical purpose infant formula, the content of each functional substance in the final product should be appropriately adjusted within the range permitted by relevant standards and specifications.

[0058] On the other hand, the present invention also provides the use of a composition comprising DHA, ARA and phospholipids in the preparation of a special medical purpose infant formula that helps to enhance and / or improve the social behavior of an individual. Wherein, the special medical purpose infant formula is the special medical purpose infant formula of any of the aforementioned embodiments of the present invention.

[0059] The present invention also provides the use of the special medical purpose infant formula in preparing a product that helps to enhance and / or improve the social behavior of an individual. The product can be the special medical purpose infant formula of any of the aforementioned solutions of the present invention, or can be other products further prepared based on the special medical purpose infant formula of the present invention.

[0060] According to some specific embodiments of the present invention, the functional components in the infant formula for special medical purposes are composed of DHA, ARA and milk lecithin, and the proportions of the components can be any of the above proportions of the present invention. The efficacy refers to enhancing and / or improving the social behavior of an individual.

[0061] According to a specific embodiment of the present invention, in the present invention, the enhancing and / or improving the social behavior of an individual includes: enhancing the social willingness and / or social ability of an individual.

[0062] According to a specific embodiment of the present invention, in the present invention, the social ability includes social adaptability (the ability of an individual to respond to and adapt to the social environment and / or social needs around him / her).

[0063] According to a specific embodiment of the present invention, the special medical purpose infant formula of the present invention is used in the preparation of a product for enhancing and / or improving the social behavior of an individual, wherein the individual is an infant or a young child. The special medical purpose infant formula of the present invention can improve the low social behavior of an individual.

[0064] In the present invention, unless otherwise specified, the infant refers to an infant of 0-12 months old, and the toddler refers to a toddler of 1-3 years old.

[0065] The infant formula food for special medical purposes provided by the present invention comprises polyunsaturated fatty acids DHA, ARA and phospholipids, which are helpful to enhance and / or improve the social behavior of an individual, and these functional components have a certain synergistic effect in enhancing and / or improving the social behavior of an individual. BRIEF DESCRIPTION OF THE DRAWINGS

[0066] Figure 1 The results of learning rate detection of each experimental group of PUFAs are shown.

[0067] Figure 2 Shows the test results of memory rate of each experimental group of PUFAs.

[0068] Figure 3 The results of the detection of the convergent frequencies of each experimental group of PUFAs are shown.

[0069] Figure 4 The results of the detection of the approaching cumulative time of each experimental group of PUFAs are shown.

[0070] Figure 5 Results showing the body contact frequency of each experimental group of PUFAs.

[0071] Figure 6 The test results showing the cumulative time of physical contact for each experimental group of PUFAs.

[0072] Figure 7 The results of the relative movement frequency test of each experimental group of PUFAs are shown.

[0073] Figure 8 The results of the relative migration accumulation time of each experimental group of PUFAs are shown.

[0074] Fig. 9 The test results showed that PUFAs and SM synergistically affected the approach frequency of individuals.

[0075] Fig.10 The test results showed that PUFAs and SM synergistically affected the individual's approach accumulation time.

[0076] Fig.11 The results showed that PUFAs and SM synergistically affected the frequency of physical contact of individuals.

[0077] Fig.12 The results showed that PUFAs and SM synergistically affected the cumulative duration of physical exposure of individuals.

[0078] Fig.13 Results showing that PUFAs and SM synergistically affect the relative movement frequency of individuals.

[0079] Fig.14 The test results showed that PUFAs and SM synergistically affected the cumulative relative movement time of individuals. DETAILED DESCRIPTION

[0080] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are for describing the specific embodiments rather than for limiting the scope of protection of the present invention.

[0081] When numerical ranges are given in the embodiments, it should be understood that the two endpoints of each numerical range and any numerical value between the two endpoints can be selected unless otherwise specified in the present invention.

[0082] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.

[0083] In addition to the specific methods, equipment, and materials used in the embodiments, based on the understanding of the prior art by those skilled in the art and the description of the present invention, any methods, equipment, and materials of the prior art that are similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention may also be used to implement the present invention.

[0084] Unless otherwise stated, the experimental methods, detection methods, and preparation methods disclosed in the present invention all adopt conventional techniques in the technical field.

[0085] In each embodiment and experiment, the DHA, ARA and phospholipids used are all commercially available food grade raw materials. Unless otherwise specified, the DHA, ARA and phospholipids mentioned in the present invention are all calculated based on the effective content of the functional components DHA, ARA and phospholipids in the raw materials.

[0086] Example 1: Tofeil Early Care Special Medical Purpose Premature / Low Birth Weight Infant Formula

[0087] In the product of this embodiment, the mass ratio of DHA to phospholipid is 0.5:1, and the mass ratio of ARA to phospholipid is 0.5:1.

[0088] The product raw materials consist of: 310 parts by weight of maltodextrin, 240 parts by weight of edible vegetable blending oil, 200 parts by weight of desalted whey powder, 90 parts by weight of hydrolyzed whey protein powder, 85 parts by weight of skimmed milk powder, 20 parts by weight of whey protein powder (α-lactalbumin powder), 10 parts by weight of casein, 4 parts by weight of phospholipids, 3.0 parts by weight of magnesium chloride, 6.0 parts by weight of complex vitamins, 1.0 parts by weight of choline chloride, 2.0 parts by weight of mineral one, 17.0 parts by weight of mineral two, 19.0 parts by weight of mineral three, 2.0 parts by weight of DHA, 2.0 parts by weight of ARA, and 0.3 parts by weight of nucleotides.

[0089] The preparation process of the product of this embodiment is as follows:

[0090] 1) Powder addition: various powder raw materials are measured according to the formula and added to the powder mixing tank through the air delivery system for storage;

[0091] 2) Vacuum powder suction: various powder materials in the powder mixing tank are sucked into the vacuum mixing tank through the vacuum system;

[0092] 3) Melting and mixing oil: put the grease specified in the formula into the oiling room according to the formula requirements. After the oil is dissolved, it is pumped into the mixed oil storage tank through the oil pump and flow meter according to the formula ratio requirements;

[0093] 4) Mixed oil storage: The mixed oil is stored in an oil storage tank under heat preservation;

[0094] 5) Weighing: Pump the mixed oil into the mixing tank through the oil pump according to the formula requirements;

[0095] 6) Nutrient dissolution and addition: minerals, vitamins, etc. are added separately, dissolved in purified water, and then pumped into the wet mixing tank. After each one is added, the addition tank and pipeline are rinsed with purified water;

[0096] 7) Filtration: The mixed liquid is filtered through a filter to remove physical impurities that may be introduced into the raw materials;

[0097] 8) Homogenization: The mixed liquid is homogenized by a homogenizer; cooled and stored;

[0098] 9) Concentrated sterilization: Use double-effect concentration during production;

[0099] 10) Liquid storage, preheating filtration, spray drying: The concentrated liquid is temporarily stored in the liquid balance tank;

[0100] 11) Fluidized bed drying and cooling;

[0101] 12) Dry mixing: Mix the weighed DHA, ARA, nucleotides and the dried and cooled powdered materials in a dry mixer to obtain the product.

[0102] Example 2: Tofeer Zaoyou special medical purpose premature / low birth weight infant formula food

[0103] In the product of this embodiment, the mass ratio of DHA to phospholipid is 4.4:1, and the mass ratio of ARA to phospholipid is 5.8:1.

[0104] The product raw materials consist of: 305 parts by weight of solid corn syrup, 216 parts by weight of edible vegetable blending oil, 200 parts by weight of desalted whey powder, 100 parts by weight of skimmed milk powder, 55 parts by weight of hydrolyzed whey protein powder, 38 parts by weight of anhydrous butter, 30 parts by weight of whey protein powder (α-lactalbumin powder), 20 parts by weight of casein, 4 parts by weight of phospholipids, 2.6 parts by weight of magnesium chloride, 4.0 parts by weight of complex vitamins, 1.0 parts by weight of choline chloride, 1.5 parts by weight of mineral one, 15.5 parts by weight of mineral two, 15.5 parts by weight of mineral three, 17.6 parts by weight of DHA, 23.2 parts by weight of ARA, and 0.3 parts by weight of nucleotides.

[0105] The preparation method is basically the same as that of Example 1.

[0106] Example 3: Tofeir Early Care Special Medical Purpose Premature / Low Birth Weight Infant Formula

[0107] In the product of this embodiment, the mass ratio of DHA to phospholipids is 8.7:1, and the mass ratio of ARA to phospholipids is 11.4:1

[0108] The product raw materials consist of: 310 parts by weight of maltodextrin, 240 parts by weight of edible vegetable blending oil, 200 parts by weight of desalted whey powder, 90 parts by weight of hydrolyzed whey protein powder, 85 parts by weight of skimmed milk powder, 20 parts by weight of whey protein powder (α-lactalbumin powder), 10 parts by weight of casein, 2 parts by weight of phospholipids, 3.0 parts by weight of magnesium chloride, 6.0 parts by weight of complex vitamins, 1.0 parts by weight of choline chloride, 2.0 parts by weight of mineral one, 17.0 parts by weight of mineral two, 19.0 parts by weight of mineral three, 17.4 parts by weight of DHA, 22.8 parts by weight of ARA, and 0.3 parts by weight of nucleotides.

[0109] The preparation method is basically the same as that of Example 1.

[0110] Example 4: Tofeer Zaoyou special medical purpose premature / low birth weight infant formula food

[0111] In the product of this embodiment, the mass ratio of DHA to phospholipid is 13:1, and the mass ratio of ARA to phospholipid is 17:1.

[0112] The product raw materials consist of: 305 parts by weight of solid corn syrup, 216 parts by weight of edible vegetable blending oil, 200 parts by weight of desalted whey powder, 100 parts by weight of skimmed milk powder, 55 parts by weight of hydrolyzed whey protein powder, 38 parts by weight of anhydrous butter, 30 parts by weight of whey protein powder (α-lactalbumin powder), 20 parts by weight of casein, 1 part by weight of phospholipids, 2.6 parts by weight of magnesium chloride, 4.0 parts by weight of complex vitamins, 1.0 part by weight of choline chloride, 1.5 parts by weight of mineral one, 15.5 parts by weight of mineral two, 15.5 parts by weight of mineral three, 13 parts by weight of DHA, 17 parts by weight of ARA, and 0.3 parts by weight of nucleotides.

[0113] The preparation method is basically the same as that of Example 1.

[0114] Experimental study on the efficacy of nutritional composition in improving individual social ability

[0115] 1. Bee species and grouping

[0116] One-day-old Italian honey bees (Apis mellifera) were used, and the intervention methods of different experimental groups were shown in Table 1 based on the diet of feed honey bees.

[0117] Table 1

[0118]

[0119] 2. Basic training of bees

[0120] 2.1 Diet preparation

[0121] Preparation of conventional diet: weigh 500 g sucrose and 10 g casein hydrolysate, dilute to 1 L with ultrapure water, stir to dissolve, filter and sterilize with a 0.22 μm filter membrane to obtain the 50% (w / v) sucrose solution containing 1% (w / v) casein hydrolysate required for the experiment.

[0122] Diet of treatment group: treatment reagent was added to the regular diet; the single-fed group was fed with a daily diet of 40 μL sugar water per bee, and the reagent was concentrated to 5 μL sterile sugar water at one time.

[0123] 2.2 Bee picking

[0124] Select honeycombs of appropriate age from the apiary, quickly transport them back to the laboratory, and place them in an incubator at 35°C and 60-80% humidity. Observe the status of the fledged bees every day from the second day (if they have not fledged, continue to culture), gently remove the fledged bees with tweezers and pack them into disposable transparent culture cups, 30 per cup, and pack enough cups according to the experimental needs.

[0125] 2.3 Bee pretreatment

[0126] The fledged bees were taken directly from the apiary, and the intestines were extracted. After adding 100ul PBS to each intestine and grinding, 50% glycerol was added in a 1:1 ratio and stored at -80°C.

[0127] Take a sterile 2mL centrifuge tube, add 990μL sterile PBS, add 10μL worker bee intestinal fluid, mix well, and finally use 50% (w / v) sterile sucrose solution to make up to 2mL mark, shake and mix well. Feed each cup of newly emerged bees with 1 tube of the above mixed solution and continue to culture in a constant temperature incubator for 24h.

[0128] 2.4 Treatment and feeding

[0129] After the colonization of intestinal fluid was completed, treatment feeding began. The CV group was fed with the CV diet, and the treatment group was fed with the treatment diet. Treatment feeding continued for 7 days. During this period, the growth status of the bees was observed daily and the diet was changed in time to ensure that the diet was sufficient. The culture conditions were: dark, 35℃, 60%-80% humidity.

[0130] Note: If the animal is gavage-fed individually, the diet placed in the feeding cup is CV diet, and only different treatment reagents are added to the gavage-fed diet.

[0131] 3. Experimental testing

[0132] Learning and memory test:

[0133] (1) Preparation of the behavioral observation room: Turn on the air conditioner and the exhaust fan of the test bench 1-2 hours before the experiment to keep the temperature of the observation room (26°C) constant and to ensure that there is no odor in the test bench.

[0134] (2) Bee starvation treatment: Each cup of test bees (no less than 40 bees) was starved for 2 hours in the morning.

[0135] (3) Bee tying: The starved bees are tied to a specific stand.

[0136] (4) PER (beak extension after starvation) reaction test: Use 50% sugar water to test whether the bees have PER (beak extension after starvation) reaction. If there is PER reaction, then odor learning can begin; if most of them do not, then continue to starve, and the cumulative starvation time should not exceed 3 hours. Bees without PER reaction are eliminated.

[0137] (5) Let the bees rest: The selected bees with PER response were placed in a behavior observation room (outside the test bench) for 15 minutes.

[0138] (6) Learning rate test: Place a single bee on the operating table, facing the tester, and let it stand for 10 seconds. At the 11th second, aim a 10mL empty syringe containing nonanol in front of the bee's antennae and give air at a constant speed for 6 seconds. At the 5th second of giving air, feed the bee with a cotton swab dipped in 50% sugar water. Feed for 2-3 seconds to ensure that the bee eats a small amount of sugar water. Record the bee's beak extension during the learning rate test to determine the bee's learning rate. Carry out 5 rounds of learning rate test according to the above method, with an interval of 10 minutes between each round.

[0139] (7) Memory rate test: The timer starts from the end of the fifth round of learning rate test, and the memory rate test begins 45 minutes later. The test operation is the same as the learning rate test, but each bee is tested twice, once with the odor of nonanol and once with n-hexanal, and the sugar water cotton swab is replaced with a clean cotton swab. The bee's beak extension during the memory rate test is recorded to determine the bee's memory rate for the odor.

[0140] (8) After the memory rate test is completed, the bees are tested for PER response, and the bees without PER response are regarded as invalid experimental bees.

[0141] Social behavior testing:

[0142] (1) Preparation of the behavioral observation room: Turn on the air conditioner and the exhaust fan of the test bench 1-2 hours before the experiment to keep the temperature of the observation room (26°C) constant and to ensure that there is no odor in the test bench.

[0143] (2) Place the experimental bees in groups of three in a transparent, breathable open field that has been prepared in advance.

[0144] (3) The open field was acclimated on the experimental table for 15 minutes, and the open field was filmed from above for 45 minutes.

[0145] (4) The above video was analyzed using the Etho Vision XT 17 animal behavior analysis system to obtain the social behavior ability data of honey bees.

[0146] 4. Experimental Results

[0147] (1) Results of the learning and memory experiment

[0148] Establish an animal model to simulate the individual development and neurodevelopment of infants and young children, and measure the indicators related to cognitive function. Learning and memory experiments are the most intuitive manifestation of cognitive function. Figure 1 As shown, the memory rate is Figure 2 As shown. The learning rate and memory rate of Example Group 1 are significantly higher than those of the control group. As the proportion of ARA in PUFAs increases, the learning rate and memory rate of Example Group 2 and Example Group 3 decrease, but there is no significant difference from the control group. As the proportion of ARA in PUFAs decreases, the learning rate and memory rate of Example Group 4 are significantly higher than those of the control group, and there is no significant difference from Example Group 1. The results show that the addition of PUFAs can significantly improve learning and memory abilities, improve intellectual development, and effectively promote the development of the nervous system.

[0149] (2) Results of social behavior experiments

[0150] Social behavior includes social willingness and / or social ability evaluation, more specifically, tendency towards social ability and social ability evaluation. Approach frequency, physical contact frequency, cumulative physical contact time, relative movement frequency, cumulative relative movement time, and cumulative approach time can directly reflect changes in an individual's social behavior ability.

[0151] The results of the effects of PUFAs on social willingness and / or social ability are as follows Figures 2 to 8 As shown. Compared with comparative example 1, the approach frequency, approach cumulative time, body contact frequency, body contact cumulative time, relative movement frequency, and relative movement cumulative time of Example Group 1 all increased; the approach frequency, approach cumulative time, body contact frequency, and relative movement frequency of Example Group 2 increased relatively; the approach frequency, body contact frequency, and relative movement frequency of Example Group 3 increased relatively; and the approach frequency of Example Group 4 showed an increasing trend. The above results show that the addition of PUFAs can improve social willingness and / or social ability.

[0152] The effects of PUFAs and SM on social behavior Figures 9 to 14As shown. Compared with comparative example 1, example group 5 and example group 1, the approach frequency, approach cumulative time, body contact frequency, body contact cumulative time, relative movement frequency and relative movement cumulative time of example group 6 were significantly increased, indicating that social behavior ability was significantly improved. The above results show that the nutritional composition of PUFAs and milk SM can significantly improve social behavior ability and can synergistically promote individual development and neural development.

[0153] The above description of the embodiments is to facilitate the understanding and use of the invention by those skilled in the art. It is obvious that those skilled in the art can easily make various modifications to these embodiments and apply the general principles described herein to other embodiments without creative work. Therefore, the present invention is not limited to the above embodiments, and improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the present invention should be within the scope of protection of the present invention.

Claims

1. A special medical purpose infant formula food, the special medical purpose infant formula food comprising DHA, ARA and phospholipids, the phospholipids are sphingomyelin and / or lecithin, wherein: The mass ratio of DHA to phospholipids is 0.5-13:1, and the mass ratio of ARA to phospholipids is 0.5-17:

1.

2. The infant formula food for special medical purposes according to claim 1, wherein: The mass ratio of DHA to ARA is 0.2-5:1, preferably 0.3-3:1, and more preferably 0.5-2.5:

1.

3. The formula food for special medical purposes for infants according to claim 1 or 2, wherein: The mass ratio of DHA to phospholipids is 0.5-8:1, and the mass ratio of ARA to phospholipids is 0.5-10:

1.

4. The formula food for special medical purposes for infants according to any one of claims 1 to 3, wherein: The amount of phospholipids in food is 20-138 mg / 100 g of food dry matter.

5. The formula food for special medical purposes for infants according to any one of claims 1 to 4, wherein: The total amount of DHA and ARA contained in food is 100-180 mg / 100 g of food dry matter.

6. The infant formula for special medical purposes according to any one of claims 1 to 5, which is a formula for premature / low birth weight infants for special medical purposes.

7. The infant formula food for special medical purposes according to claim 6, wherein: Based on 1000 parts by weight of the formula food, the raw materials include: 0-200 parts by weight of hydrolyzed whey protein powder, 0-50 parts by weight of whey protein powder, 100-500 parts by weight of desalted whey powder, 0-100 parts by weight of casein; 0-10 parts by weight of phospholipids, 0-50 parts by weight of anhydrous butter, 0-400 parts by weight of solid corn syrup, 0-400 parts by weight of maltodextrin, 0-150 parts by weight of sunflower oil, 0-40 parts by weight of corn oil, 200 parts by weight of soybean oil. ~80 weight parts, medium chain triglycerides 0~100 weight parts, tryptophan 0~10 weight parts, arginine 0~10 weight parts, complex vitamins 1~5 weight parts, magnesium chloride 0~3 weight parts, choline chloride 0~3 weight parts, mineral one 0~2 weight parts, mineral two 1~12 weight parts, mineral three 0~15 weight parts, DHA 0~15 weight parts, ARA 0~20 weight parts, nucleotides 0~1.5 weight parts, lactoferrin 0~2 weight parts.

8. Use of the infant formula for special medical purposes according to any one of claims 1 to 7 in the preparation of a product that helps to enhance and / or improve the social behavior of an individual.

9. The use according to claim 8, wherein: The said enhancing and / or improving individual social behavior includes: enhancing individual social willingness and / or social ability; Preferably, the social ability includes social interaction ability and / or social adaptability.

10. The use according to claim 8 or 9, wherein: The individual is an infant or a young child.

Images